医学
危险系数
肝细胞癌
临床终点
伦瓦提尼
内科学
随机对照试验
中期分析
索拉非尼
胃肠病学
置信区间
外科
作者
Zhenwei Peng,Wenzhe Fan,Bowen Zhu,Guoying Wang,Junhui Sun,Chengjiang Xiao,Fuxi Huang,Rong Tang,Yu Cheng,Zhen Huang,Yuchuang Liang,Huishuang Fan,Liangliang Qiao,Fuliang Li,Wenquan Zhuang,Baogang Peng,Jiping Wang,Jiaping Li,Ming Kuang
摘要
The addition of TACE to LEN improves clinical outcomes and is a potential first-line treatment for patients with advanced HCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI